Insulet Co. (NASDAQ:PODD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have received an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $272.81.

PODD has been the topic of a number of recent analyst reports. Canaccord Genuity Group increased their price target on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Sanford C. Bernstein started coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target on the stock. Citigroup lifted their price target on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. BTIG Research lifted their price objective on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, TD Cowen increased their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.47% of the stock is owned by insiders.

Institutional Investors Weigh In On Insulet

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC boosted its position in shares of Insulet by 92.6% during the 2nd quarter. Private Advisor Group LLC now owns 3,187 shares of the medical instruments supplier’s stock valued at $643,000 after purchasing an additional 1,532 shares in the last quarter. BOKF NA grew its holdings in shares of Insulet by 10.3% during the 2nd quarter. BOKF NA now owns 10,703 shares of the medical instruments supplier’s stock valued at $2,160,000 after acquiring an additional 1,001 shares in the last quarter. Thoroughbred Financial Services LLC purchased a new position in Insulet in the second quarter valued at about $407,000. Oppenheimer Asset Management Inc. raised its position in Insulet by 16.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 20,622 shares of the medical instruments supplier’s stock valued at $4,162,000 after acquiring an additional 2,943 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in shares of Insulet by 4.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 87,718 shares of the medical instruments supplier’s stock valued at $17,702,000 after purchasing an additional 4,065 shares in the last quarter.

Insulet Stock Performance

NASDAQ PODD opened at $275.81 on Monday. The business’s 50-day moving average price is $266.30 and its 200 day moving average price is $232.96. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet has a twelve month low of $160.19 and a twelve month high of $279.77. The company has a market capitalization of $19.35 billion, a PE ratio of 47.23, a price-to-earnings-growth ratio of 3.41 and a beta of 1.22.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.